Evidence map›Paper›PMID 42125304›Full record

ArticleJournal of asthma and allergy2026

Effectiveness of FF/UMEC/VI versus ICS/LABA in Patients with Uncontrolled Asthma Treated in Routine Clinical Practice (PERFORM): A Pragmatic Randomized Controlled Trial.

Erika Penz, Stephen G Noorduyn, Alison C Moore, Hiroyuki Nagase, Jodie Crawford, Mary Woessner, Lydia Demetriou, Nicola Brown, David Slade, Gabriel Garcia and 2 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06372496 (A Phase 4, 52-week), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06372496 phase4active not recruitingnot on this map

A Phase 4, 52-week (Primary Analysis at 24-weeks), Randomized, Stratified, Open-label, Active-controlled, Parallel-group, Effectiveness Study, Comparing FF/UMEC/VI With Non-ellipta Usual Care (ICS/LABA) in Adult Participants With Uncontrolled Asthma

TypeinterventionalSponsorGlaxoSmithKlineRan2024 to 2027Enrolled1,366ConditionsAsthmaArmsFluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Erika PenzDepartment of Medicine, Division of Respirology and Sleep Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Stephen G NoorduynGlobal Real-World Evidence, GSK, Mississauga, ON, Canada.
Alison C MooreGlobal Medical Affairs, General Medicines, GSK, London, UK.
Hiroyuki NagaseDivision of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan.ORCID 0000-0002-0296-5901
Jodie CrawfordDevelopment Biostatistics, GSK, London, UK.
Mary WoessnerGSK, Durham, NC, USA.
Lydia DemetriouGlobal Clinical Operations, GSK, London, UK.ORCID 0009-0004-4665-279X
Nicola BrownClinical Sciences, Respiratory, GSK, London, UK.
David SladeRespiratory Clinical Research Unit, GSK, Collegeville, PA, USA.
Gabriel GarciaRespiratory Research Center, La Plata, Argentina.
Alan P BaptistDivision of Allergy and Immunology, Henry Ford Health, Detroit, MI, USA.
John J OppenheimerUniversity of Medicine and Dentistry of New Jersey-Rutgers, Newark, NJ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Asthma guidelines recommend stepwise escalation of inhaled corticosteroid/long-acting β Methods: PERFORM (GSK219912/NCT06372496) is a randomized, open-label, active-controlled, 52-week, global pragmatic trial including adults (18-75 years) with uncontrolled, infrequently exacerbating asthma, previously untreated or treated with non-ELLIPTA ICS or ICS/LABA in the 3-months pre-randomization. Powered primary and secondary endpoints were change from baseline in trough forced expiratory volume in 1 second (FEV Results: Overall, 1236 patients (mean age: 48.9 years; 68.6% female) were included in this W24 primary analysis (FF/UMEC/VI: N=619; ICS/LABA: N=617). At baseline mean FEV Conclusion: This pragmatic RCT demonstrated significant improvements in lung function and asthma control with FF/UMEC/VI versus ICS/LABA in uncontrolled and infrequently exacerbating patients treated in a routine practice setting. These findings further inform the evidence base for optimized use of FF/UMEC/VI.

Indexed as

asthma controllung functionreal-world settingsingle-inhaler triple therapy

Identifiers

PMID42125304
PMCPMC13159957

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.